Current Report Filing (8-k)
December 12 2016 - 7:41AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_____________________________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event
reported): December 12, 2016 (December 9, 2016)
_____________________________________________
Neuralstem, Inc.
(Exact name of registrant as specified
in Charter)
Delaware
|
|
001-33672
|
|
52-2007292
|
(State or other jurisdiction
of
incorporation or organization)
|
|
(Commission File No.)
|
|
(IRS Employee Identification No.)
|
20271 Goldenrod Lane, 2
nd
Floor, Germantown, Maryland 20876
(Address of Principal Executive Offices)
(301) 366-4960
(Issuer Telephone number)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
|
|
|
|
Item 3.02 Unregistered Sale
of Equity Securities.
On December 12, 2016, Neuralstem, Inc.
(“Company”) announced the closing of the strategic investment by Tianjin Pharmaceuticals Group International Holdings
Co., LTD. (“Tianjin”). As previously disclosed in the Company’s Current Report on Form 8-K filed with the Securities
Exchange Commission on September 12, 2016 (“Prior 8-K”), on December 12, 2016, the Company issued to Tianjin, an aggregate
of (i) 28,500,000 shares of the Company’s common stock (“Common Stock”), at a price per share of $0.253 and (ii)
1,000,000 shares of Series A 4.5% Convertible Preferred Stock (“Series A Preferred Stock”) with a stated value of $12.7895
per share and which are immediately convertible into an aggregate of 50,551,383 shares of the Company’s Common Stock, subject
to certain limitations on conversion based on Tianjin’s voting interest (the “Offering”).
As part of the transaction on December
9, 2016, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series A 4.5% Convertible Preferred
Stock (the “Certificate of Designation”) to its Amended and Restated Certificate of Incorporation with the Secretary
of State of the State of Delaware, authorizing and establishing the rights, preferences and privileges of the Series A Preferred
Stock. A Copy of the Certificate of Designation is attached to this Report as exhibit 3.01 and is incorporated herein in its entirety
by reference.
A copy of the securities purchase agreement
and is contained in exhibit 10.01 to the Prior 8-K, which is incorporated herein in its entirety by reference.
Item 3.03 Material Modification
to Rights of Security Holders.
The information set forth in Items 3.02 and 5.03 is hereby incorporated
by reference into this Item 3.03 in its entirety.
Item 5.03 Amendment to Articles
of Incorporation or Bylaws.
The information set forth in Items 1.01
and 3.03 is hereby incorporated by reference into this Item 5.03 in its entirety.
Item 7.01 Regulation FD Disclosure.
On December 12, 2016, the Company announced
the Offering in a press release. A copy of the press release is attached to this report as Exhibit 99.01.
The information contained in this Item
7.01 to this Current Report on Form 8-K and the exhibit attached hereto pertaining to this item shall not be deemed to be “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject
to the liabilities of that section, nor shall such information or such exhibits be deemed incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference
in such a filing. The information set forth in the exhibits to this Form 8-K relating to this item 7.01 shall not be deemed an
admission as to the materiality of any information in this report that is required to be disclosed solely to satisfy the requirements
of Regulation FD.
Item 9.01 Financial Statements
and Exhibits.
|
|
|
|
|
Exhibit
No.
|
|
Description
|
|
|
3.01
|
|
Series A 4.5% Convertible Preferred Stock Certificate of Designation
|
|
|
99.01
|
|
Press Release dated December 12, 2016.
|
|
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto
duly authorized.
Date:
|
December 12, 2016
|
Neuralstem, Inc.
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Richard Daly
|
|
|
|
By: Richard Daly
|
|
|
|
Chief Executive Officer
|
|
|
|
|
|
INDEX OF EXHIBITS
|
|
|
|
|
Exhibit
No.
|
|
Description
|
|
|
3.01
|
|
Series A 4.5% Convertible Preferred Stock Certificate of Designation
|
|
|
99.01
|
|
Press Release dated December 12, 2016.
|
|
|
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From Apr 2023 to Apr 2024